JP2009518021A5 - - Google Patents

Download PDF

Info

Publication number
JP2009518021A5
JP2009518021A5 JP2008543852A JP2008543852A JP2009518021A5 JP 2009518021 A5 JP2009518021 A5 JP 2009518021A5 JP 2008543852 A JP2008543852 A JP 2008543852A JP 2008543852 A JP2008543852 A JP 2008543852A JP 2009518021 A5 JP2009518021 A5 JP 2009518021A5
Authority
JP
Japan
Prior art keywords
cells
antigen
cell
tcr
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008543852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518021A (ja
Filing date
Publication date
Priority claimed from EP05111928A external-priority patent/EP1795599A1/en
Application filed filed Critical
Publication of JP2009518021A publication Critical patent/JP2009518021A/ja
Publication of JP2009518021A5 publication Critical patent/JP2009518021A5/ja
Withdrawn legal-status Critical Current

Links

JP2008543852A 2005-12-09 2006-12-11 抗原特異的エフェクターｔ細胞の生成法 Withdrawn JP2009518021A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111928A EP1795599A1 (en) 2005-12-09 2005-12-09 Methods for generating antigen-specific effector T cells
US77958806P 2006-03-06 2006-03-06
PCT/EP2006/069549 WO2007065957A2 (en) 2005-12-09 2006-12-11 Methods for generating antigen-specific effector t cells

Publications (2)

Publication Number Publication Date
JP2009518021A JP2009518021A (ja) 2009-05-07
JP2009518021A5 true JP2009518021A5 (https=) 2010-01-28

Family

ID=36691455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543852A Withdrawn JP2009518021A (ja) 2005-12-09 2006-12-11 抗原特異的エフェクターｔ細胞の生成法

Country Status (8)

Country Link
US (1) US20090226404A1 (https=)
EP (2) EP1795599A1 (https=)
JP (1) JP2009518021A (https=)
KR (1) KR20080077272A (https=)
CN (1) CN101415827A (https=)
AU (1) AU2006323961A1 (https=)
CA (1) CA2631785A1 (https=)
WO (1) WO2007065957A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
EP2126054B1 (en) 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
US9809797B2 (en) 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
EP2090659A1 (en) * 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof
WO2009108341A1 (en) 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
US20140161782A1 (en) * 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
PL3736329T3 (pl) * 2012-09-11 2022-07-18 Corning Incorporated Zużywalne krioprezerwowane komórki wykazujące przejściową nadekspresję genu(-ów) kodującego(-ych) białko(-a) transportera leku i/lub enzym(y) metabolizujący(-e) lek
CN102911267B (zh) * 2012-09-19 2014-04-02 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
JP6580579B2 (ja) 2014-01-29 2019-09-25 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体を発現する細胞を生産する方法および組成物
WO2016095934A2 (en) * 2014-12-14 2016-06-23 El Abd Hisham Mohamed Magdy A novel genetic device to engineer cell behavior
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos
WO2017120428A2 (en) 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
JP6952225B2 (ja) * 2016-03-18 2021-10-20 北海道公立大学法人 札幌医科大学 Ｔ細胞レセプターとその利用
CN118147079A (zh) * 2016-03-31 2024-06-07 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
WO2017208018A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
US12358962B2 (en) * 2017-05-02 2025-07-15 Immunomic Therapeutics, Inc. Lamp constructs comprising cancer antigens
CN107630005A (zh) * 2017-09-19 2018-01-26 深圳市北科生物科技有限公司 表达plac1特异性tcr的t细胞及其应用
CN107557339A (zh) * 2017-09-19 2018-01-09 深圳市北科生物科技有限公司 特异性识别plac1的t细胞及其与细胞因子的联合的应用
CA3076261A1 (en) 2017-09-19 2019-03-28 Admare Vintageco1 Investments Ltd. Anti-hla-a2 antibodies and methods of using the same
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
US12134637B2 (en) 2018-07-12 2024-11-05 Bgi Shenzhen MART-1(27-35) epitope-specific T cell receptor
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
CN112941030B (zh) * 2021-01-25 2023-08-08 吉林大学 一种抗原特异性Treg及其制备方法和应用
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2024008274A1 (en) * 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
CN117797253A (zh) * 2024-02-29 2024-04-02 诺未科技（北京）有限公司 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
EP1188825A1 (en) * 2000-09-18 2002-03-20 Universiteit Leiden T cell receptor transfer into a candidate effector cell or a precursor thereof
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
KR20060126516A (ko) * 2003-11-25 2006-12-07 아르고스 쎄라퓨틱스 인코포레이티드 Ｍｒｎａ로 전달이입된 항원제시세포

Similar Documents

Publication Publication Date Title
JP2009518021A5 (https=)
Gao et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy
Zhang et al. Targeting natural killer cells for tumor immunotherapy
US10351612B2 (en) Interleukin 15 as selectable marker for gene transfer in lymphocytes
Fang et al. Challenges of NK cell-based immunotherapy in the new era
Wei et al. Emerging strategies in TCR-engineered T cells
ES2816450T3 (es) Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
Redeker et al. Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
ES2907581T3 (es) Método mejorado para la generación de células genéticamente modificadas
Wu et al. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
JP2020062054A (ja) ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
van der Veken et al. αβ T cell receptor transfer to γδ T cells generates functional effector cells without mixed TCR dimers in vivo
JP2017533706A5 (https=)
CN109952309A (zh) 用于细胞治疗的组成型活性细胞因子受体
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
Yuan et al. Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
CN120344652A (zh) 利用慢病毒载体转染的新型大规模car-t免疫细胞制造方法
Wei et al. CAR-macrophage cell therapy: a new era of hope for pancreatic cancer
US20240398950A1 (en) Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells
Khodayari et al. Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Shin et al. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy
WO2025067472A1 (en) Methods of culturing gamma delta t cells
WO2024193459A1 (en) METHODS OF CULTURING Vδ1 T CELLS
WO2022153295A1 (en) Improved adoptive cell transfer therapy for cancer